摘要:
A method for increasing the placental blood flow, which comprises administering a human-originated antithrombin-III. The human-originated antithrombin-III increases the placental blood flow in mammals and particularly improves intrauterine growth retardation caused by a decreased blood flow. The method is highly safe to the mother and fetus, since it uses human-originated AT-III as an active ingredient, thereby enabling effective and safe treatment of intrauterine growth retardation (IUGR) and the like.
摘要:
Quinolin-2-yl benzoic acid compounds which are useful as intermediates of quinoline compounds having angiotensin II antagonist activity prepared by decarboxylating 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds in which a carboxyl group bonded to a phenyl group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both rings may have one or more substituents inert to the decarboxylation reaction.
摘要:
A method for decoloring a recombinant human serum albumin by treating the albumin with a reducing agent is disclosed. Also, a method for decoloring a recombinant human serum albumin by treating the albumin with a method removing free polysaccharides with a cation exchanger followed by heat treatment is disclosed. The present invention provides a recombinant human serum albumin, coloring of which is fully suppressed by preventing binding of certain coloring components, which are contained in the raw materials or contaminants secreted by a microorganism, to human serum albumin so as not to cause coloring of the human serum albumin.
摘要:
A method for highly purifying human serum albumin (HSA), which comprises bringing a fraction containing HSA produced by genetic engineering into contact with a chelating chromatography carrier bound with copper ions, and eluting the HSA adsorbed by the carrier with a buffer containing ammonium chloride as an atagonist and having a pH of about 5-7.According to the method of the present invention, a component derived from yeast, which cannot be sufficiently removed by conventional purification methods for HSA produced by genetic engineering, can be removed from HSA produced by genetic engineering, and a highly purified HSA can be provided.
摘要:
A 1,4-benzoxazine-2-acetic acid compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, a method for production thereof, and a pharmaceutical composition, an aldose reductase inhibitor and an agent for the prevention and/or treatment of the complications of diabetes, which contain the same. The compound (I) of the present invention and pharmaceutically acceptable salts thereof have aldose reductase inhibitory action and are superior in safety. Accordingly, they are useful as an agent for the prevention and/or treatment of the complications of diabetes such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis.
摘要:
Disclosed are processes for germ-destroying air, water and food, including a germ-destroying step using an isothiocyanic acid ester, germicidal fibers and plastic products and processes for preparing the germicidal fibers and plastic products, fumigants and fumigating processes, as well as germicidal gas composition containing an isothiocyanic acid ester, a process for the preparation thereof and an apparatus for use with the process therefor.
摘要:
Novel signal peptides capable of functioning in yeasts have the amino acid sequence:Met-A.sub.1 -A.sub.2 -X-B-C-D-E-Fwherein A.sub.1 is a peptide chain composed of 1-3 amino acids each selected from the group consisting of Arg, Ser, Lys and His, A.sub.2 is a peptide chain composed of 1-3 amino acids, X is a peptide chain composed of 8-10 hydrophobic amino acids, B is Pro or Ser, C is Gly or Pro, D Cys, Ala, Leu, Ser, Thr and Val, E is Trp or Gln and F is Ala or Gly. DNA sequences coding for these signal peptides can be used for the secretory expression of heterologous proteins in yeasts.
摘要:
An aminopyridine compound represented by the formula: ##STR1## wherein n represents 0 or 1; Z represents .dbd.S, .dbd.NCN or .dbd.CHNO.sub.2 ; R.sub.1 represents --NR.sub.3 R.sub.4, --NHNR.sub.3 R.sub.4, --NHCONHR.sub.3 or --NHSO.sub.2 R.sub.3 ; R.sub.2 represents H, or substituted or unsubstituted alkyl; R.sub.3 and R.sub.4, which may be the same or different, represent H, substituted or unsubstituted alkyl, aryl, substituted or unsubstituted acyl or alkoxycarbonyl group; and R.sub.3 and R.sub.4 may form a heterocyclic ring together with a nitrogen atom to which R.sub.3 and R.sub.4 are bound, through another heteroatom or without it; an optical isomer thereof or art acid salt thereof, which is excellent in pharmacological effect and repressed in side effects as a drug for circulatory diseases.
摘要翻译:由下式表示的氨基吡啶化合物:其中n表示0或1; Z表示= S,= NCN或= CHNO2; R 1表示-NR 3 R 4,-NHNR 3 R 4,-NHCONHR 3或-NHSO 2 R 3; R 2表示H或取代或未取代的烷基; R 3和R 4可以相同或不同,表示H,取代或未取代的烷基,芳基,取代或未取代的酰基或烷氧基羰基; 并且R 3和R 4可以与R3和R4连接的氮原子一起通过另一个杂原子或不与其形成杂环; 其光学异构体或其酸性盐,其药理作用优异,作为循环系统疾病药物的副作用被抑制。
摘要:
There is provided an ophthalmic preparation comprising a fat emulsion containing flurbiprofen or its derivative such as ester as an active ingredient.
摘要:
A pharmaceutical composition comprising a benzoyl urea compound (A) selected from the group consisting of a benzoyl urea compound (I) having the formula: ##STR1## wherein X is a halogen atom, a nitro group or a trifluoromethyl group, provided that when Y is a nitro group, X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom, and A is a .dbd.CH-- group or a nitrogen atom, and a benzoyl urea compound (II) having the formula: ##STR2## wherein each of X.sub.1 and X.sub.2 is a hydrogen atom, a halogen atom or a nitro group, provided that when Y is a nitro group, X.sub.1 is a hydrogen atom, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, and Z is a hydrogen atom, a halogen atom or a trifluoromethyl group, as an active ingredient; a nonionic surfactant as a dispersant; and at least one member selected from the group consisting of a saccharide, a saccharide alcohol, silicic anhydride and a nonionic surfactant, as a disintegrator.